Your browser doesn't support javascript.
loading
Overexpression of KLHL22 correlates with poor prognosis in patients with triple-negative breast cancer.
Zhang, Tianzhi; Liu, Jiani; Wang, Jin; Zhang, Chao.
Afiliación
  • Zhang T; Department of Pathology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
  • Liu J; The Cancer Center of The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, China.
  • Wang J; Department of Breast Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
  • Zhang C; Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Transl Cancer Res ; 13(2): 798-807, 2024 Feb 29.
Article en En | MEDLINE | ID: mdl-38482450
ABSTRACT

Background:

Kelch-like family member 22 (KLHL22) is a protein-coding gene that is responsible for several Mendelian diseases and has been reported to promote tumorigenesis and aging. The purpose of this study was to investigate its expression in triple-negative breast cancer (TNBC) and its prognostic significance.

Methods:

Immunohistochemistry (IHC) was performed to examine the expression levels of KLHL22 in 146 patients with TNBC. The Chi-squared test was used to analyze the correlations between KLHL22 expression level and clinicopathological features, and the Kaplan-Meier survival analysis and Cox multivariate regression model were used to analyze the prognostic significance of KLHL22 in patients with TNBC.

Results:

The results of immunohistochemical analysis showed that the high expression rate of KLHL22 protein in TNBC was 56.85% (83/146). Further analysis revealed a significantly positive correlation (P<0.05) between KLHL22 expression and primary tumor and regional lymph node status, clinical stage, and relapse. Kaplan-Meier survival analysis revealed that patients with low KLHL22 expression had a longer mean survival time than those with high KLHL22 expression (147.93 vs. 90.1 months; P<0.05). In the multivariate analysis, KLHL22 level, P53 expression, and clinical stage were found to be independent prognostic factors for overall survival (P<0.05), while clinical stage and KLHL22 level were independent prognostic factors for progression-free survival (P<0.05).

Conclusions:

The present study concludes that KLHL22 may serve as a biomarker for poor prognosis in patients with TNBC.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Transl Cancer Res Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Transl Cancer Res Año: 2024 Tipo del documento: Article